Please Wait.....
Report
Kidney Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2)), By Region & Competition, 2020-2030F
Market Report I 2025-03-28 I 185 Pages I TechSci Research
Global Kidney Cancer Drugs Market was valued at USD 7.15 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.45% through 2030. Kidney cancer, also known as renal cell carcinoma, is a type of cancer that originates in the kidneys, the bean-shaped organs responsible for filtering waste and excess fluids from the blood to form urine. Kidney cancer, medically termed renal cell carcinoma (RCC), is a complex and challenging disease that demands effective treatment strategies. As medical research advances and pharmaceutical innovation accelerates, several key drivers are propelling the growth and evolution of the kidney cancer drugs market. Targeted therapies are a class of drugs designed to inhibit specific molecules or pathways that are crucial for cancer cell growth and survival. In kidney cancer, targeted therapies have revolutionized treatment. Examples include tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and axitinib. These drugs disrupt the signaling pathways that promote tumor growth and angiogenesis (formation of new blood vessels). The landscape of kidney cancer treatment has been dramatically transformed by the introduction of these drugs. Patients who once faced limited options now have access to a range of therapies that offer improved survival rates and enhanced quality of life. As research continues, the kidney cancer drugs market is poised for further advancements. Combination therapies, personalized medicine approaches, and the integration of novel targets are on the horizon. Additionally, the ongoing collaboration among researchers, pharmaceutical companies, healthcare organizations, and patient advocacy groups will continue to shape the development of innovative therapies and ultimately lead to better outcomes for patients facing kidney cancer.
Key Market Drivers
Rising Incidence of Kidney Cancer
The global kidney cancer market is experiencing significant expansion, largely driven by the rising incidence of kidney cancer worldwide. In 2022, kidney cancer accounted for 434,840 newly diagnosed cases globally, making it the 14th most prevalent cancer worldwide. It ranked as the 10th most diagnosed cancer among men and the 13th among women, underscoring its significant impact on global healthcare systems and oncology markets. The increasing number of renal cell carcinoma (RCC) cases-the most common type of kidney cancer-has created a growing demand for advanced diagnostics, innovative therapeutics, and improved healthcare infrastructure. This trend is not only shaping market dynamics but also influencing the strategic direction of pharmaceutical companies, healthcare providers, and investors. The global population is aging at an unprecedented rate. Between 1974 and 2024, the proportion of individuals aged 65 and older nearly doubled, rising from 5.5% to 10.3%, and age is a significant risk factor for kidney cancer. With higher life expectancy, the number of kidney cancer cases is expected to increase, driving demand for effective treatment options. Developed regions such as North America and Europe report higher incidence rates due to advanced screening programs and improved diagnostic capabilities. Meanwhile, emerging economies in Asia-Pacific are seeing rising cases due to lifestyle changes and increasing industrialization, leading to a higher demand for cancer therapeutics.
Key Market Challenges
Resistance and Treatment Heterogeneity
Despite the advancements in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Over time, tumors can evolve and adapt, rendering once-effective therapies ineffective. This challenge underscores the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Additionally, kidney cancer is not a homogeneous disease. Different subtypes and genetic variations contribute to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor that requires a deep understanding of tumor biology and personalized medicine approaches.
Key Market Trends
Personalized Medicine Revolution
The era of personalized medicine has dawned upon the field of kidney cancer treatment, offering immense promise for improved patient outcomes. With the advent of precision oncology, the one-size-fits-all approach to treatment is giving way to tailored interventions that account for individual genetic profiles and biomarker expression. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. Armed with this information, they can prescribe targeted therapies that are more likely to elicit a favorable response. This shift towards personalized treatment approaches not only enhances the efficacy of drugs but also minimizes the potential for adverse effects.
Key Market Players
- Novartis AG
- Pfizer Inc.
- Bayer AG
- Genentech Inc.
- Bristol-Myers Squibb
- Eisai Co., Ltd.
- Exelixis Inc
- Prometheus Laboratories Inc
- Glaxosmithkline PLC.
- F. Hoffmann-LA Roche AG
Report Scope:
In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Kidney Cancer Drugs Market, By Therapeutic Class:
o Targeted Therapy
o Immunotherapy
o Chemotherapy
- Kidney Cancer Drugs Market, By Pharmacologic Class:
o Angiogenesis Inhibitors
o Monoclonal Antibodies
o mTOR Inhibitors
o Cytokine Immunotherapy (IL-2)
- Kidney Cancer Drugs Market, By Region:
o North America
United States
Canada
Mexico
o Asia-Pacific
China
India
South Korea
Australia
Japan
o Europe
Germany
France
United Kingdom
Spain
Italy
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.
Available Customizations:
Global Kidney Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Kidney Cancer Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))
5.2.3. By Company (2024)
5.2.4. By Region
5.3. Market Map
6. North America Kidney Cancer Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutic Class
6.2.2. By Pharmacologic Class
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Kidney Cancer Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapeutic Class
6.3.1.2.2. By Pharmacologic Class
6.3.2. Mexico Kidney Cancer Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapeutic Class
6.3.2.2.2. By Pharmacologic Class
6.3.3. Canada Kidney Cancer Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapeutic Class
6.3.3.2.2. By Pharmacologic Class
7. Europe Kidney Cancer Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Therapeutic Class
7.2.2. By Pharmacologic Class
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Kidney Cancer Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapeutic Class
7.3.1.2.2. By Pharmacologic Class
7.3.2. Germany Kidney Cancer Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapeutic Class
7.3.2.2.2. By Pharmacologic Class
7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapeutic Class
7.3.3.2.2. By Pharmacologic Class
7.3.4. Italy Kidney Cancer Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapeutic Class
7.3.4.2.2. By Pharmacologic Class
7.3.5. Spain Kidney Cancer Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapeutic Class
7.3.5.2.2. By Pharmacologic Class
8. Asia-Pacific Kidney Cancer Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Therapeutic Class
8.2.2. By Pharmacologic Class
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Kidney Cancer Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapeutic Class
8.3.1.2.2. By Pharmacologic Class
8.3.2. India Kidney Cancer Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapeutic Class
8.3.2.2.2. By Pharmacologic Class
8.3.3. South Korea Kidney Cancer Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapeutic Class
8.3.3.2.2. By Pharmacologic Class
8.3.4. Japan Kidney Cancer Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapeutic Class
8.3.4.2.2. By Pharmacologic Class
8.3.5. Australia Kidney Cancer Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapeutic Class
8.3.5.2.2. By Pharmacologic Class
9. South America Kidney Cancer Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutic Class
9.2.2. By Pharmacologic Class
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Kidney Cancer Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapeutic Class
9.3.1.2.2. By Pharmacologic Class
9.3.2. Argentina Kidney Cancer Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapeutic Class
9.3.2.2.2. By Pharmacologic Class
9.3.3. Colombia Kidney Cancer Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapeutic Class
9.3.3.2.2. By Pharmacologic Class
10. Middle East and Africa Kidney Cancer Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutic Class
10.2.2. By Pharmacologic Class
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Kidney Cancer Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapeutic Class
10.3.1.2.2. By Pharmacologic Class
10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapeutic Class
10.3.2.2.2. By Pharmacologic Class
10.3.3. UAE Kidney Cancer Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapeutic Class
10.3.3.2.2. By Pharmacologic Class
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. Competitive Landscape
15.1. Novartis AG
15.1.1. Business Overview
15.1.2. Product & Service Offerings
15.1.3. Recent Developments
15.1.4. Financials (If Listed)
15.1.5. Key Personnel
15.1.6. SWOT Analysis
15.2. Pfizer Inc.
15.3. Bayer AG
15.4. Genentech Inc.
15.5. Bristol-Myers Squibb
15.6. Eisai Co., Ltd.
15.7. Exelixis Inc
15.8. Prometheus Laboratories Inc
15.9. Glaxosmithkline PLC.
15.10. F. Hoffmann-LA Roche AG
16. Strategic Recommendations
17. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security